|
Volumn 23, Issue 4, 2016, Pages 569-570
|
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
METFORMIN;
ANTIDIABETIC AGENT;
ANTINEOPLASTIC AGENT;
A549 CELL LINE;
ANTINEOPLASTIC ACTIVITY;
CANCER SURVIVAL;
DIABETIC PATIENT;
HUMAN;
LETTER;
MALIGNANT NEOPLASTIC DISEASE;
MURINE MODEL;
NONHUMAN;
OXIDATIVE PHOSPHORYLATION;
PRIORITY JOURNAL;
TUMOR MICROENVIRONMENT;
ANIMAL;
C57BL MOUSE;
DISEASE MODEL;
DOSE RESPONSE;
MOUSE;
NEOPLASM;
PATHOLOGY;
ANIMALS;
ANTINEOPLASTIC AGENTS;
DISEASE MODELS, ANIMAL;
DOSE-RESPONSE RELATIONSHIP, DRUG;
HUMANS;
HYPOGLYCEMIC AGENTS;
METFORMIN;
MICE;
MICE, INBRED C57BL;
NEOPLASMS;
|
EID: 84963656397
PISSN: 15504131
EISSN: 19327420
Source Type: Journal
DOI: 10.1016/j.cmet.2016.03.010 Document Type: Letter |
Times cited : (139)
|
References (10)
|